Prediction of response to primary chemotherapy for operable breast cancer

M. Colleoni, E. Orvieto, F. Nolé,, L. Orlando, I. Minchella, G. Viale, G. Peruzzotti, C. Robertson, C. Noberasco, V. Galimberti, V. Sacchini, P. Veronesi, S. Zurrida, R. Orecchia, A. Goldhirsch

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

The use of primary systemic cytotoxics leads to a high remission rate in patients with breast cancer. Response was identified as an important variable associated with survival. Thus, features which predict response, are potentially relevant for planning treatments and improving survival. Retrospectively, we investigated several histopathological features (expression of oestrogen and progesterone receptors, Mib1, bcl-2, c-erbB-2, and p53) prior to two programmes of either sequential preoperative chemotherapy (doxorubicin plus cyclophosphamide) and radiotherapy (Group A), or preoperative chemotherapy (5-fluorouracil, folinic acid and vinorelbine) alone (Group B) in patients with operable breast cancer. After three courses, patients with a partial or complete response were given a further three courses, which was followed for patients in Group A by radiotherapy 50 Gy plus a boost of 10 Gy. All patients were submitted to surgery after completion of preoperative treatment and pathology material from 73 patients (median age, 49 years, range, 30-70; performance status, 0-1; 68 T2, 5 T3) was obtained. The overall response rate according to radiological and clinical evaluation was 59% (68% for Group A and 49% for Group B). 12 of 14 patients with p53-positive turnouts and 31 of 59 with p53-negative tumours responded (P= 0.04). 6 of 7 patients with elevated c-erbB-2 had a response compared with 37 of 66 patients in the group with c-erbB-2 negative tumours (P= 0.03). Mib1 expression decreased substantially (≥ 50%) in 25 patients during treatment, of whom 20 responded compared with 21 of 48 patients with a lower decrease (P = 0.04). Response was observed in 28 of 37 patients with high baseline Mib1 (> 20%) and in 15 of 36 patients in the low Mib1 group (P= 0.05). Finally, 32 of 44 tumours with low expression of progesterone receptors responded compared with 11 of 29 tumours with high receptors expression (P = 0.05). These markers might be useful for tailoring primary and postsurgical systemic treatments.

Original languageEnglish
Pages (from-to)574-579
Number of pages6
JournalEuropean Journal of Cancer
Volume35
Issue number4
DOIs
Publication statusPublished - Apr 1999

Fingerprint

Breast Neoplasms
Drug Therapy
Progesterone Receptors
Neoplasms
Radiotherapy
Survival
Leucovorin
Therapeutics
Fluorouracil
Estrogen Receptors
Doxorubicin
Cyclophosphamide
Pathology

Keywords

  • Cyclophosphamide
  • Doxorubicin
  • Predictive features
  • Preoperative chemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Prediction of response to primary chemotherapy for operable breast cancer. / Colleoni, M.; Orvieto, E.; Nolé, F.; Orlando, L.; Minchella, I.; Viale, G.; Peruzzotti, G.; Robertson, C.; Noberasco, C.; Galimberti, V.; Sacchini, V.; Veronesi, P.; Zurrida, S.; Orecchia, R.; Goldhirsch, A.

In: European Journal of Cancer, Vol. 35, No. 4, 04.1999, p. 574-579.

Research output: Contribution to journalArticle

Colleoni, M. ; Orvieto, E. ; Nolé, F. ; Orlando, L. ; Minchella, I. ; Viale, G. ; Peruzzotti, G. ; Robertson, C. ; Noberasco, C. ; Galimberti, V. ; Sacchini, V. ; Veronesi, P. ; Zurrida, S. ; Orecchia, R. ; Goldhirsch, A. / Prediction of response to primary chemotherapy for operable breast cancer. In: European Journal of Cancer. 1999 ; Vol. 35, No. 4. pp. 574-579.
@article{30773fc8af2d4cffb5da089074219ee0,
title = "Prediction of response to primary chemotherapy for operable breast cancer",
abstract = "The use of primary systemic cytotoxics leads to a high remission rate in patients with breast cancer. Response was identified as an important variable associated with survival. Thus, features which predict response, are potentially relevant for planning treatments and improving survival. Retrospectively, we investigated several histopathological features (expression of oestrogen and progesterone receptors, Mib1, bcl-2, c-erbB-2, and p53) prior to two programmes of either sequential preoperative chemotherapy (doxorubicin plus cyclophosphamide) and radiotherapy (Group A), or preoperative chemotherapy (5-fluorouracil, folinic acid and vinorelbine) alone (Group B) in patients with operable breast cancer. After three courses, patients with a partial or complete response were given a further three courses, which was followed for patients in Group A by radiotherapy 50 Gy plus a boost of 10 Gy. All patients were submitted to surgery after completion of preoperative treatment and pathology material from 73 patients (median age, 49 years, range, 30-70; performance status, 0-1; 68 T2, 5 T3) was obtained. The overall response rate according to radiological and clinical evaluation was 59{\%} (68{\%} for Group A and 49{\%} for Group B). 12 of 14 patients with p53-positive turnouts and 31 of 59 with p53-negative tumours responded (P= 0.04). 6 of 7 patients with elevated c-erbB-2 had a response compared with 37 of 66 patients in the group with c-erbB-2 negative tumours (P= 0.03). Mib1 expression decreased substantially (≥ 50{\%}) in 25 patients during treatment, of whom 20 responded compared with 21 of 48 patients with a lower decrease (P = 0.04). Response was observed in 28 of 37 patients with high baseline Mib1 (> 20{\%}) and in 15 of 36 patients in the low Mib1 group (P= 0.05). Finally, 32 of 44 tumours with low expression of progesterone receptors responded compared with 11 of 29 tumours with high receptors expression (P = 0.05). These markers might be useful for tailoring primary and postsurgical systemic treatments.",
keywords = "Cyclophosphamide, Doxorubicin, Predictive features, Preoperative chemotherapy",
author = "M. Colleoni and E. Orvieto and F. Nol{\'e}, and L. Orlando and I. Minchella and G. Viale and G. Peruzzotti and C. Robertson and C. Noberasco and V. Galimberti and V. Sacchini and P. Veronesi and S. Zurrida and R. Orecchia and A. Goldhirsch",
year = "1999",
month = "4",
doi = "10.1016/S0959-8049(99)00005-2",
language = "English",
volume = "35",
pages = "574--579",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "4",

}

TY - JOUR

T1 - Prediction of response to primary chemotherapy for operable breast cancer

AU - Colleoni, M.

AU - Orvieto, E.

AU - Nolé,, F.

AU - Orlando, L.

AU - Minchella, I.

AU - Viale, G.

AU - Peruzzotti, G.

AU - Robertson, C.

AU - Noberasco, C.

AU - Galimberti, V.

AU - Sacchini, V.

AU - Veronesi, P.

AU - Zurrida, S.

AU - Orecchia, R.

AU - Goldhirsch, A.

PY - 1999/4

Y1 - 1999/4

N2 - The use of primary systemic cytotoxics leads to a high remission rate in patients with breast cancer. Response was identified as an important variable associated with survival. Thus, features which predict response, are potentially relevant for planning treatments and improving survival. Retrospectively, we investigated several histopathological features (expression of oestrogen and progesterone receptors, Mib1, bcl-2, c-erbB-2, and p53) prior to two programmes of either sequential preoperative chemotherapy (doxorubicin plus cyclophosphamide) and radiotherapy (Group A), or preoperative chemotherapy (5-fluorouracil, folinic acid and vinorelbine) alone (Group B) in patients with operable breast cancer. After three courses, patients with a partial or complete response were given a further three courses, which was followed for patients in Group A by radiotherapy 50 Gy plus a boost of 10 Gy. All patients were submitted to surgery after completion of preoperative treatment and pathology material from 73 patients (median age, 49 years, range, 30-70; performance status, 0-1; 68 T2, 5 T3) was obtained. The overall response rate according to radiological and clinical evaluation was 59% (68% for Group A and 49% for Group B). 12 of 14 patients with p53-positive turnouts and 31 of 59 with p53-negative tumours responded (P= 0.04). 6 of 7 patients with elevated c-erbB-2 had a response compared with 37 of 66 patients in the group with c-erbB-2 negative tumours (P= 0.03). Mib1 expression decreased substantially (≥ 50%) in 25 patients during treatment, of whom 20 responded compared with 21 of 48 patients with a lower decrease (P = 0.04). Response was observed in 28 of 37 patients with high baseline Mib1 (> 20%) and in 15 of 36 patients in the low Mib1 group (P= 0.05). Finally, 32 of 44 tumours with low expression of progesterone receptors responded compared with 11 of 29 tumours with high receptors expression (P = 0.05). These markers might be useful for tailoring primary and postsurgical systemic treatments.

AB - The use of primary systemic cytotoxics leads to a high remission rate in patients with breast cancer. Response was identified as an important variable associated with survival. Thus, features which predict response, are potentially relevant for planning treatments and improving survival. Retrospectively, we investigated several histopathological features (expression of oestrogen and progesterone receptors, Mib1, bcl-2, c-erbB-2, and p53) prior to two programmes of either sequential preoperative chemotherapy (doxorubicin plus cyclophosphamide) and radiotherapy (Group A), or preoperative chemotherapy (5-fluorouracil, folinic acid and vinorelbine) alone (Group B) in patients with operable breast cancer. After three courses, patients with a partial or complete response were given a further three courses, which was followed for patients in Group A by radiotherapy 50 Gy plus a boost of 10 Gy. All patients were submitted to surgery after completion of preoperative treatment and pathology material from 73 patients (median age, 49 years, range, 30-70; performance status, 0-1; 68 T2, 5 T3) was obtained. The overall response rate according to radiological and clinical evaluation was 59% (68% for Group A and 49% for Group B). 12 of 14 patients with p53-positive turnouts and 31 of 59 with p53-negative tumours responded (P= 0.04). 6 of 7 patients with elevated c-erbB-2 had a response compared with 37 of 66 patients in the group with c-erbB-2 negative tumours (P= 0.03). Mib1 expression decreased substantially (≥ 50%) in 25 patients during treatment, of whom 20 responded compared with 21 of 48 patients with a lower decrease (P = 0.04). Response was observed in 28 of 37 patients with high baseline Mib1 (> 20%) and in 15 of 36 patients in the low Mib1 group (P= 0.05). Finally, 32 of 44 tumours with low expression of progesterone receptors responded compared with 11 of 29 tumours with high receptors expression (P = 0.05). These markers might be useful for tailoring primary and postsurgical systemic treatments.

KW - Cyclophosphamide

KW - Doxorubicin

KW - Predictive features

KW - Preoperative chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0033118545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033118545&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(99)00005-2

DO - 10.1016/S0959-8049(99)00005-2

M3 - Article

C2 - 10492630

AN - SCOPUS:0033118545

VL - 35

SP - 574

EP - 579

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 4

ER -